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Abstract: The aims of this study were to: (1) determine whether replacement of cow’s 
milk protein with soy resolves Chronic Functional Constipation (CFC); and (2) investigate 
the effects of cow’s milk β casein A1 and cow’s milk β casein A2 on CFC. Children 
diagnosed with CFC were recruited to one of two crossover trials: Trial 1 compared the 
effects of cow’s milk and soy milk; Trial 2 compared the effects of cow’s milk β casein A1 
and cow’s milk β casein A2. Resolution of constipation was defined as greater than  
eight bowel motions during a two week intervention. Thirteen children (18 to 144 months) 
participated in Trial 1 (6 boys, 7 girls). Nine participants who completed the soy epoch all 
experienced resolution (p < 0.05). Thirty-nine children (21 to 144 months) participated in 
Trial 2 (25 boys, 14 girls). Resolution of constipation was highest during the washout 
epoch, 81%; followed by cow’s milk β casein A2, 79%; and cow’s milk β casein A1, 57%; 
however, the proportions did not differ statistically. The results of Trial 1 demonstrate an 
association between CFC and cow’s milk consumption but Trial 2 failed to show an effect 
from type of casein. Some other component in cow’s milk common to both A1 and A2 
milk may be causing a problem in these susceptible children. 
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1. Introduction 
Chronic functional constipation (CFC), defined as having one bowel motion every 3 to  
15 days [1], occurs commonly in children. The frequency of CFC has been estimated to be as high as 
36% of children who attend a consultation with a paediatrician [2]. A sensitivity to cow’s milk protein 
(CMP) has been proposed as a possible cause for CFC [3]. A potential link between CMP and 
constipation was first referred to in the allergy literature as early as the 1950’s [4]. Our systematic 
review of the literature from 1980 to 2008 assessing the evidence for a causal relationship between 
CMP intake and CFC in children found a small body of evidence which was suggestive rather than 
conclusive [5]. Randomised trials are needed to provide higher level evidence.  
Iacono and colleagues used a double-blind crossover trial design to compare the response to cow’s 
milk with that of soy milk in 65 children with chronic constipation [3]. Thirty three children were 
commenced on cow’s milk and 32 on soy milk for two weeks, followed by an unrestricted diet for  
one week, and then they were given the alternate milk for another two weeks. Constipation resolved 
(greater than 8 bowel motions per fortnight) for 68% of children consuming soy milk, but not for any 
of those consuming cow’s milk [3]. The researchers observed that children whose constipation 
resolved on the soy milk possessed a number of symptoms associated with cow’s milk protein 
allergy/intolerance at baseline, suggesting a pre-existing abnormality of the immune system. The main 
limitation of this study was the uncontrolled nature of the diet in between the two epochs. To date, the 
Iacono study has not been replicated by other researchers. The first stage of this current study, Trial 1, 
aimed to evaluate whether total removal of cow’s milk from the diet and substitution with soy milk, 
could resolve chronic constipation in children with CFC resistant to usual treatment in Australia. 
The Iacono findings suggested that CMP consumption was a problem in these children, and 
proposed that the basis of CFC involved an allergic immune response to the ingested protein. 
Approximately 80% of total protein in cow’s milk is casein, and 30% to 35% of this is in the form of  
β-caseinwhich may contain an allergenic component [6]. β-Casein consists of a chain of 209 amino 
acids which can differ in structure depending on the breed of cowas a result of an adenine-cystosine 
substitution mutation giving β casein A2 translating in to a proline at position 67 rather than  
a histidine [7,8]. The β casein A1histidine variant allows enzymatic cleavage with production of  
a seven amino acid peptide called “β casomorphin 7” (BCM7) which has been shown to affect gut 
transit time [7,8]. It is hypothesised that in susceptible people, leakage of the peptide into the gut might 
result in CFC. In Trial 2, we aimed to investigate the effect of cow’s milk β casein A1 and cow’s milk 
β casein A2 on children with CFC resistant to traditional treatment. 
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2. Method 
2.1. Study Design 
Two separate crossover clinical trials were conducted. Trial 1 compared the effect of cow’s milk 
and soy milk on CFC and was conducted in Tamworth, New South Wales. The second trial compared 
cow’s milk β casein A1 with cow’s milk β casein A2 and was conducted in Newcastle, New South 
Wales. With the exception of milk type, the study epochs were identical and the crossover design used 
in both trials is described below. As each child and their family consented to participate in the study 
they were assigned (according to whether the participants’ day of birth was odd or even), to pathway 1 
or pathway 2 for each trial, by the research assistant (Figure 1). All researchers were blinded to the 
assignment. Ethical approval for the study was granted by Hunter New England Area Health Service 
Ethics Committee and the University of Newcastle Human Research Ethics Committee in 2005 
(Reference 03/08/13/12/3.23). The aim was to recruit 30 children to Trial 1 and 40 children to Trial 2. 
The pathway of the study is shown in Figure 1. 
Figure 1. Trials and pathways to which participants were assigned in the cross-over study. 
 
2.2. Participants 
Children (1–12 years) diagnosed by a paediatrician with CFC, defined as less than eight bowel 
motions per fortnight [3], unresolved by medications or diet, were recruited from medical and health 
services within the Hunter New England Region of New South Wales, from 2005 to 2007. Potential 
participants were made aware of the study by approved information sheets available in the surgery and 
via the clinicians. Families were provided with an information package about the study including:  
a participant information sheet; a sheet describing the milk free diet; and a reply-paid envelope. 
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Participation in the study commenced when the researcher received a signed consent form. Children 
with Hirschsprungs disease, Cerebral Palsy, Coeliac disease and using medications known to cause 
constipation were excluded from the study. Children previously prescribed laxatives for chronic 
functional constipation withheld these for the duration of the trial.  
2.3. Protocol 
The trial procedure is shown in Figure 2. A detailed medical history was taken by the diagnosing 
paediatrician prior to commencing the trial. A detailed diet history, including amount of milk and dairy 
products usually consumed, was taken by the dietitian. Participants and/or their parents were supplied 
with the assigned milk for each of the two week trial periods and advised how to consume at least  
400 mL of this milk each day and educated by a dietitian in how to avoid all other sources of CMP, 
without varying their usual fibre and fluid intake. The first two-week trial period was followed by a 
two-week washout period to remove possible confounders. The washout period was free of soy and 
cow’s milk protein, β casein A1 and cow’s milk β casein A2. Participants were encouraged to consume 
an additional 400 mL of other fluid during the washout period in place of the intervention milk to 
prevent dehydration. They were offered calcium supplementation during this period. After a two-week 
washout period, participants were switched to the alternate milk epoch for another two weeks. 
Researchers were unaware of the order of treatment and milk in commercial containers was rewrapped 
by the research assistant to promote double blinding.  
Figure 2. Flowchart of the trial protocol. 
 
2.4. Primary Outcome Measures  
2.4.1. Bowel Movements 
The average number of bowel motions per fortnight, prior to commencement of the study, was 
checked to assess eligibility and noted. A “Constipation Study Patient Diary” using the Bristol Stool 
Scale [9], previously validated against gut transit time [10–12], was kept by participants or their 
parents for the duration of the six week study. Records were kept of the number of bowel movements 
per day; whether straining was required to pass the motion; stool form and appearance in comparison 
Patients referred to the study by GP, Paediatrician or Continence Nurse  
 
Medical history taken by paediatric continence nurse or paediatrician, 
including onset of constipation, frequency and duration of breastfeeding, personal and  
family history of atopy 
 
Nutritional assessment conducted by a dietitian 
 
Start protocol, 1 type of milk for 2 weeks 
 
2 week washout 
 
Other type of milk for 2 weeks 
 
End of protocol 
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to diagrams on the back of the diary; and symptoms of abdominal pain/discomfort and bloating.  
A clinical outcome was defined as eight or more bowel movements during a two week treatment 
period [3]. 
2.4.2. Other Participant Data 
Data collected included: onset, symptoms and duration of the constipation; medication history; 
frequency and duration of breast feeding; personal and family history of allergy and intolerance.  
2.5. Statistical Analysis 
The statistics package SPSS™ version 16.0 was used for analysis. A linear mixed method analysis 
of the data was conducted to determine the effect of the treatments for the numeric outcome variables. 
Repeated measures analysis of variance was used to compare each of the three milk epochs; In Trial 1: 
soy milk, milk free and cow’s milk; In Trial 2: cow’s milk β casein A1, milk free and cow’s milk β 
casein A2. Verification of this analysis was conducted using contrasts and pair wise comparisons. 
Categorical versions of the numeric variables were used to statistically compare the number of bowel 
motions during the three two week trial periods for each milk epoch. The McNemar test for paired 
observations was used. Continuous variables were tested for normality then paired t-tests and  
non-parametric tests used to compare the number of bowel motions per participant per fortnight on 
each of the milk epochs. The Friedman test and Wilcoxon Ranked Sign were used to verify analysis 
conducted by the parametric tests. 
3. Results 
3.1. Participant Characteristics at Baseline 
Fourteen children were initially recruited to Trial 1, with one later excluded due to a subsequent 
diagnosis of coeliac disease leaving 13 participants (6 boys, 7 girls). The mean (SD) age of participants 
was 80 (±38) months. The characteristics, family history and clinical history of these participants are 
shown in Table 1. Initial clinical assessment of participants showed that a number had symptoms 
associated with cow’s milk protein allergy (CMPA) or intolerance (CMPI) [13]. 
Table 1. Age, family history and clinical history of 13 participants recruited to Trial 1 and 
39 participants recruited to Trial 2. 
Characteristics and History Participants Reporting Characteristic of History 
 Trial 1 (n = 13) Trial 2 (n = 39) 
 n % n % 
Age 
<3 years 
4–6 years 
7–9 years 
10–12 years 
 
2 
4 
5 
2 
 
15.3 
30.7 
38.4 
15.3 
 
10 
19 
6 
4 
 
25.6 
48.7 
15.3 
10.2 
Family history of CMPA or CMPI 4 30.7 7 17.9 
Personal history of CMPA or CMPI 0 0 3 7.7 
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Table 1. Cont. 
Physical symptoms of intolerance to cow’s milk 
Dermatitis, eczema, rhinitis   20 51.3 
History of asthma 6 46.1 16 41.0 
History of ear infections 9 69.2 9 23.1 
Grommets  2 15.3 2 5.1 
History of tonsillitis/throat infections 5 38.4 4 10.2 
Tonsils removed 1 7.6 2 5.1 
Adenoids removed  3 23.0 3 7.7 
Gestation and birth characteristics 
Maternal thrush during pregnancy 
Delivered by caesarian section 
Breastfed 
 
2 
3 
6 
 
15.3 
23.0 
46.1 
 
4 
8 
12 
 
10.3 
20.5 
30.7 
Development delayed 3 23.0 11 28.2 
Behavioural issues 
Consultation with psychologist 
Psychosocial disruption of the family  
 
2 
6 
 
15.3 
46.1 
 
6 
17 
 
15.4 
43.6 
History of recurrent UTI’s 3 23.07 9 23.1 
Constipation symptoms 
Soiling or encopresis 
 
13 
 
100 
 
25 
 
64.1 
Abdominal pain 9 69.2 28 71.8 
Anal pain  7 53.8 27 69.2 
Anal bleeding 3 23.0 14 35.9 
Diagnosis of perianal dermatitis 1 7.6 8 20.5 
Other current symptoms  
Poor appetite 
Nausea or vomiting 
 
5 
5 
 
38.4 
38.4 
 
22 
8 
 
56.4 
20.5 
Forty participants were recruited to Trial 2, with one excluded from the study due to a subsequent 
diagnosis of coeliac disease leaving 39 participants, 25 males and 14 females. The mean age of 
participants was 67 months (±35 months) and the range was 21 to 143 months. The characteristics, 
family history and clinical history of these participants are also shown in Table 1. Seven participants 
reported a family history of cow’s milk protein allergy or intolerance. Initial clinical assessment of 
participants showed that a number had symptoms associated with cow’s milk protein allergy or 
intolerance, including, asthma, ear infections and grommets [2] but only three of these participants had 
been diagnosed with cow’s milk protein allergy or intolerance.  
3.2. Primary Outcome Measure: Resolution of Constipation 
3.2.1. Trial 1 
Nine of the thirteen participants returned constipation diaries for the study period and eight 
completed all three dietary epochs. The number of bowel motions per dietary epoch is shown for each 
participant in Figure 3a. 
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Figure 3. (a) Number of stools per fortnight at baseline and on each of the study conditions for Trial 1; (b) Number of stools per fortnight at 
baseline and on each of the study conditions for Trial 2. 
a 
 
Condition order: 
Soy Milk/Washout/Cows Milk 
n = 2 
Condition order: 
Cows Milk/Washout/Soy Milk 
n = 2 
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Figure 3. Cont. 
b 
 
No. of stools, Number per fortnight; * Participant did not complete the full 2 weeks of this condition due to the reoccurrence of constipation; (N) Number 
of days on intervention milk before dropping out; ** Dropped out of the trial after a successful outcome on soy milk; - Missing values. 
 
Condition order: 
A1/Washout/A2 
n = 11 
Condition order: 
A2/Washout/A1 
n = 15 
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The mean number of bowel motions increased from baseline for all participants. No participant 
experienced constipation (less than 8 bowel motions per fortnight) on the soy milk epoch. During the 
milk free washout, only one participant experienced constipation and this occurred when the washout 
followed the cow’s milk epoch. Three participants who showed no constipation on soy milk or 
washout met the definition for constipation during the cow’s milk epoch. The ninth participant left the 
study after experiencing resolution of constipation on soy milk in the first epochand could not be 
included in the analysis. Using the Greenhouse-Geisser adjustment, the differences in mean  
number of bowel motions between the three epochs (shown in Table 2) was statistically significant,  
F (1.88, 13.1) = 4.58, p = 0.03. Follow up statistical analysis, using contrasts and pair wise 
comparisons and a Repeated Measures ANOVA identified differences in the number of bowel motions 
per fortnight between the three epochs as shown in Table 3. To further verify the analysis above, the 
Freidman test for three related variables was applied to the number of bowel motions in each of the 
three epochs and showed statistical significance (x
2
(2) = 9.6, p = 0.01). The number of motions for 
each subject during the cow’s milk versus the soy milk epoch for each participant is plotted below  
in Figure 4. 
Table 2. Cases of resolution (greater than 8 bowel motions per fortnight) of constipation 
and mean bowel motions during a 2 week condition for Trial 1 and Trial 2. 
Trial 1 Trial 2  
Bowel 
Movements and 
Descriptions 
Pre  
trial 1 
n = 9 
Cow’s 
milk  
n = 8 3 
Washout 2 
n = 9 3 
Soy Milk 
n = 9 
p 
Pre  
trial 1 
n = 26 
Cow’s milk 
β casein A1 
n = 22 3 
Washout 2 
n = 23 3 
Cow’s milk 
β casein A2 
n = 25 3 
p 
Resolution of 
Constipation n (%) 
0 (0) 5 (62) 8 (100) 9 (100) 0.01 * 0 (0) 14 (64) 18 (78) 16 (64) 0.12 4 
Bowel motions per 
fortnight M (SD) 
5.1 (1.4) 9.9 (4.4) 13.0 (5.2) 15.1 (5.0) 0.03 ** 4.42 (1.55) 10.05 (5.75) 10.43 (5.05) 10.56 (5.24) 
0.62 5 
0.42 6 
* Wilcoxon Signed Rank Sum; ** Paired t-test; 1 Reported by participants prior to trial commencement; 2 The washout period acted as a 
condition in itself as it was free from all milk and soy protein; 3 The number of participants in each condition is not the same because 
some participants ceased participation in the study after the various conditions; 4 Resolution of constipation = >8 bowel motions per 
fortnight; 5 The difference between the two milk epochs cow’s milk β casein A1 and for cow’s milk casein A2; 6 The difference between 
the 3 epochs. 
Table 3. Clinical outcomes for participants who completed all 3 conditions of Trial 2: cow’s 
milk β casein A1 condition compared with the cow’s milk β casein A2 condition, n = 21. 
 Cow’s Milk β Casein A2 
  Less than  
8 motions 
More than  
8 motions 
Row 
Total 
Cow’s milk 
β casein A1  
Less than 8 motions 3 * 6 9 
More than 8 bowel motions 3 ** 9 12 
Column Total 6 15 21 
n = 3 *, <8 on both milks; n = 3 **, More than 8 on A1 and less than 8 on A2; n = 6, <8 on A1 and >8 on A2;  
n = 9, >8 on A1 and A2. 
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Figure 4. Total number of bowel motions per fortnight during the soy condition versus the 
cow’s milk condition. 
 
The line of no change, that is, the point at which the number of motions during the cow’s milk 
epoch equalled the number of motions during the soy milk epoch is shown in Figure 4. All nine 
participants experienced more bowel motions in the soy epoch versus the cow’s milk epoch. 
Participant number 5 had an unusually high number of bowel motions per fortnight during the soy 
epoch. When this participant was removed from the data set, the results were no longer normally 
distributed so the tests were repeated using non-parametric analysis with all subjects, with the 
Repeated Measures ANOVA, (p = 0.02). Follow up analyses using the Wilcoxon signed rank tests 
showed that the significant difference found with the Friedman test was due to the difference between 
the soy and cow’s milk epochs. This held for both analyses, with and without subject 5. See Table 2 
for p values. 
3.2.2. Trial 2 
Twenty-six participants returned constipation diaries for the study period. Thirteen other 
participants dropped out at various stages of the trial. Reasons included: inability to strictly follow the 
milk free diet, identified allergy to soy milk during the trial, achieving a resolution on soy milk 
resulting in withdrawal from the study and death in the family. The rate of constipation resolution 
(greater than 8 bowel motions per fortnight) and the mean number of bowel motions per fortnight under 
each epoch for participants are shown in Table 2. The number of bowel motions per dietary epoch is 
shown for each participant is shown in Figure 3b. 
The highest observed resolutions, 18 (78%) participants, occurred during the washout period, when 
no cow’s milk protein was being consumed. There was no significant difference in the mean number 
of bowel motions per fortnight for each of the epochs, although there was a tendency to a higher 
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number for the cow’s milk β casein A2 epoch. The mean number of bowel motions increased from 
baseline for all participants as shown in Table 2. 
Table 3 shows twelve participants (57%) experienced more than 8 bowel motions on cow’s milk β 
casein A1, while fifteen participants (71%) experienced more than 8 bowel motions on cow’s milk β 
casein A2. However, because each participant participated in both epochs in the study there is more to 
be understood aboutthe data in Table 3. Examining the results jointly, that is, for the A1 and A2 
epochs together, three participants (10%) did not resolve during either the cow’s milk β casein A1 or 
cow’s milk β casein A2 epochs. Nine participants (43%) resolved under both epochs. Further,  
six (29%) participants resolved on cow’s milk β casein A2 but did not resolve on cow’s milk β casein 
A1 (four out of these six commenced on A2). Three (14%) did not resolve on cow’s milk β casein A2, 
but did resolve on cow’s milk β casein A1 (two out of the three commenced on A1). It is these last two 
cells that provide the information as to whether A2 differs from A1 and is assessed using the 
McNemar test for paired categorical data. Based on this analysis, the percentages that resolved on 
cow’s milk β casein A2, 15 participants (71%) and cow’s milk casein A1, 12 participants (57%), there 
was no significant difference between the two p = 0.51. 
The difference between washout and the two milk epochs cow’s milk β casein A1, (p = 0.12) and 
for cow’s milk casein A2, (p = 0.62) was not significant. There was a higher percentage resolution on 
cow’s milk β casein A2 than cow’s milk β casein A1, but the results were not statistically significant. 
Neither was there statistical significance between the three epochs in motions per fortnight for cow’s 
milk β casein A1, washout and cow’s milk casein A2, F (2, 39.2) = 0.90, p = 0.42. As neither of the 
three epochs was demonstrably different, nor different to washout, it appears that participating in the 
trial was the most important effect, raising the percentage of constipation resolved (greater than  
8 bowel motions per fortnight) from zero prior to the trial to an average level of (57 + 71 + 82)/3 = 70% 
over the 6 weeks of the study. Secondary outcome measures, such as symptoms associated with 
constipation on the Bristol Stool Scale were recorded; however, there were no distinguishable trends or 
patterns between participants (data not shown). 
4. Discussion 
The first trial showed that removal of CMP from the diet of children with CFC significantly 
increased the number of bowel motions and improved constipation, suggesting that CMP played a role 
in CFC for these children. All participants in this study experienced resolution (greater than 8 bowel 
motions per fortnight) of constipation on soy milk compared with the 68% that resolved on soy milk in 
the study by Iacono and colleagues [3]. The difference may be due to the fact that the Iacono study was 
not completely CMP free for its duration because the background diet was unrestricted. In addition, the 
brief period between epochs in Iacono’s study went uncontrolled and the number of bowel motions 
during this period was not reported. Our study provided a two week CMP free washout period with 
monitored bowel motions to avoid these limitations. The fact that only three out of eight children in 
Trial 1 experienced constipation during the cow’s milk epochcould be explained by a trial effect  
(as discussed below) or by a mixed model of cow’s milk sensitivity, where children with resolution of 
constipation (greater than 8 bowel motions per fortnight) on this epochmay be exhibiting CMP 
intolerance rather than CMP allergy. The trial effector Hawthorne effect, (that is, being involved in a 
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study and applying more attention to the problem, may have helped to resolve the problem) possibly 
occurred in both studies with the overall trend to an increased number of bowel motions from baseline, 
regardless of epoch. It is possible that consuming a CMP free diet for six weeks may have decreased 
the total amount of CMP consumed in comparison to participant’s pre-trial diet for some participants 
(even with the extra 400 mL for the cow’s milk epoch) below a tolerance threshold, or that the 
requirement to consume 400 mL of fluid in each epoch resulted in an increase in usual total fluid 
intake (despite being advised to keep total fluid intake stable) and therefore hydration. Future studies 
should monitor daily fluid intake as a compliance measure (before and during the study).  
Trial 2 was the first experiment of its kind to compare the effects of β casein A1 and β casein A2 
moiety on children with CFC. While the mean number of bowel motions increased and some 
participants reached resolutionof constipation (greater than 8 motions per fortnight) (probably due to 
the trial effect outlined above), bothepochs reproduced the results of the cow’s milk β casein A1 epoch 
in Trial 1. It seems that it is not the β casein moiety, in cow’s milk that is causing constipation or if it 
is, it is not the section that differs between the A1 and A2 variants. Some other component in cow’s 
milk common to both A1 and A2 milk but not to soy milk may be causing a problem in these 
susceptible children. Resolution (greater than 8 bowel motions per fortnight) with both cow’s milk β 
casein A1 and cow’s milk β casein A2 epochs suggests that these children are able to tolerate some 
CMP before the symptom occurs and possibly 400 mL was insufficient to induce an effect.  
The strengths of this trial were the crossover design with subjects acting as their own controls, the 
two-week washout period free from cow’s milk and soy milk and their derivatives, and the six week 
record of bowel outcome measures. A number of limitations have been identified. While a double 
blind protocol was followed, it is unlikely that it was achieved in Trial 1 due to the easily identifiable 
taste and smell of soy milk. This may have had a positive psychological effect on some participants’ 
constipation if they believed cow’s milk to be the cause. This was not the case in Trail 2 given that A1 
and A2 milk are identical in appearance, flavor and smell. The assignment of participants while even 
in those recruited, was not even in the final participant population, due to a bias where those who 
commenced on cow’s milk being more likely to drop out of the study. 
The study had a high participant burden which may have contributed to lack of completion in both 
trials. Nutrition intervention studies are notorious for the challenge in retention caused by the burden 
of dietary change [14], resulting in relatively small numbers of completers. The rigors of a dietary trial 
based on exclusion of a nutrient, CMP, commonly found not only in its most obvious dairy sources but 
also hidden in many processed foods in Australia proved to be difficult for many participants. Further 
burden was placed on participants by asking them to collect data regarding their or their child’s bowel 
motions on a daily basis. While the families who ceased participation were not formally interviewed, 
some reported reasons for dropout including: death in the family, trial length, participating only to 
obtain results of the baseline blood test; and an allergic reaction to soy milk (reported by one 
participant). For at least one participant, achieving an improved bowel function on soy milk resulted in 
a withdrawal from the study after the first epochso that the commencing milk affected the research 
process, if not the results.  
In any further research investigations, CFC should be clearly and commonly defined. Replications 
of this study should commence the protocol with a two-week washout period. Bowel motions should 
be recorded and reported during this time. Higher volumes of cow’s milk need to be consumed to 
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determine the threshold that causes constipation in CMPI and actual milk and other fluid consumption 
needs to be recorded daily. Participants should be well monitored to assist with compliance and 
increase retention. Investigations into the immunological or biochemical mechanism occurring in CFC 
are required, including investigations of the intolerance reactions and how they affect nerves in the 
gastrointestinal tract.  
5. Conclusions 
The results of Trial 1 demonstrate an association between CFC and cow’s milk consumption while 
trial 2 failed to show an effect from type of casein. Some other component in cow’s milk common to 
both A1 and A2 milk may be causing a problem in these susceptible children. Investigations into the 
immunological or biochemical mechanism occurring in CFC are required, including investigations of 
the intolerance reactions and how they affect nerves in the gastrointestinal tract. 
Acknowledgements 
This research study was conducted as part of the requirements for Masters of Medical Science by 
the first author under the supervision of the other authors. Financial assistance was provided by the 
Primary Health Care Research and Development Program and The University of Newcastle 
Department of Rural Health. Soy milk was donated by Sanitarium. Many thanks to Kim Colyvas, 
Statistician, The University of Newcastle, for the statistical analysis for this study. 
References 
1. Behrman, R.E.; Kliegman, R.M.; Jenson, H.B. Nelson’s Text Book of Paediatric; Saunders: 
Philadelphia, PA, USA, 2004. 
2. Motta, M. Intolerance of cow’s milk and chronic constipation in children. Int. Paediatr. 2001, 16, 
66–71. 
3. Iacono, G.; Cavataio, F.; Montalto, G.; Florena, A.; Tumminello, M.; Soresi, M.;  
Notarbartolo, A.; Carroccio, A. Intolerance of cow’s milk and chronic constipation in children.  
N. Engl. J. Med. 1998, 339, 1100–1104. 
4. Clein, N. Cow’s milk allergy in infants. Pediatr. Clin. North Am. 1954, 4, 949–962. 
5. Crowley, E.; Williams, L.; Roberts, T.; Jones, P.; Dunstan, R. Evidence for a role of cow’s milk 
consumption in chronic functional constipation in children: Systematic review of the literature 
from 1980 to 2006. Nutr. Diet. 2008, 65, 29–35. 
6. Woodford, K. Devil in the Milk; Craig Potton Publishing: Nelson, New Zealand, 2007. 
7. Hartwig, A.; Teschemacher, H.; Lehmann, W.; Gauly, M.; Erhadt, G. Influence of Genetic 
Polymorphisms in Bovine Milk on the Occurence of Bioactive Peptides. In Milk Protein 
Polymorphism, International Dairy Federation Special Publication 9702; International Dairy 
Federation: Brussels, Belgium, 1997; pp. 459–460. 
8. Jinsmaa, Y.; Yoshikawa, M. Enzymatic release of neocasomorphin and beta-casomorphin from 
bovine beta-casein. Peptides 1999, 20, 957–962. 
9. Heaton, K.; Thompson, W. Irritable Bowel Syndrome; Health Press: Oxford, UK, 1999. 
Nutrients 2013, 5 266 
 
10. Degen, L.; Phillips, S. How well does stool form reflect colonic transit? Gut 1996, 39, 109–113. 
11. Heaton, K.; Ghosh, S.; Braddon, F. How bad are the symptoms and bowel disfunction of patients 
with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. 
Gut 1991, 32, 73–79. 
12. O’Donnell, L.; Heaton, K. Pseudo-diarrhoea in the irritable bowel syndrome: Patients records of 
stool form reflect transit time while stool frequency does not. Gut 1988, 29, A1455. 
13. Hill, D.J.; Duke, A.M.; Hosking, C.S.; Hudson, I.L. Clinical manifestations of cows’ milk allergy 
in childhood. II. The diagnostic value of skin tests and RAST. Clin. Allergy 1988, 18, 481–490. 
14. Keller, C.; Gonzales, A.; Fleuriet, K. Retention of minority participants in clinical research. West. 
J. Nurs. Res. 2005, 27, 292–306. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
